Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02394964 · ClinicalTrials.gov registry record
The Human Microbiome in Immune-Mediated Diseases
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 75
- Enrollment target
NCT02394964: Completed study, sponsored by Yale University.
NCT02394964 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02394964 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
Study Summary
The immune system is influenced by the commensal microbes that live in the gut and on the skin. This study aims to characterize the microbiota of subjects with autoimmune disease in order to determine whether certain microbial species may cause or worsen immune-mediated diseases
Primary Outcome
Difference in disease group vs. control commensal bacteria will be compared by looking at the relative abundances of the microbiota
Interventions
- OTHER Sample Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2014-11 |
| Est. Completion | 2023-12 |
What the finished NCT02394964 record still lists
NCT02394964 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Sample Collection is the first listed.
NCT02394964 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02394964 about?
NCT02394964 is a clinical study titled "The Human Microbiome in Immune-Mediated Diseases". The immune system is influenced by the commensal microbes that live in the gut and on the skin. This study aims to characterize the microbiota of subjects with autoimmune disease in order to determine whether certain microbial species may cause or worsen immune-mediated diseases
What is the current status of trial NCT02394964?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2014-11. Estimated completion is 2023-12.
What interventions are being tested in trial NCT02394964?
The interventions under investigation include: Sample Collection (OTHER).
Who is sponsoring clinical trial NCT02394964?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia